Semaglutide

Research Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk. It is the active ingredient in Ozempic (for type 2 diabetes) and Wegovy (for weight management), both FDA-approved medications. Semaglutide is also available from research peptide vendors as a lyophilized powder for investigational use.

The peptide works by mimicking the incretin hormone GLP-1, which is naturally released from the gut after eating. It binds to GLP-1 receptors in the pancreas to stimulate insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce hunger. A key structural modification — an albumin-binding fatty acid side chain — gives semaglutide a half-life of approximately 7 days, enabling once-weekly dosing.

Semaglutide has generated enormous public interest due to its dramatic weight loss results in clinical trials and subsequent celebrity adoption. It is the highest-search-volume peptide by a significant margin, though it differs from most research peptides in that it has full FDA approval and is available by prescription.

Research Dosage Protocols

Semaglutide is an FDA-approved prescription medication available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations. Research-grade semaglutide is sold as lyophilized powder.

In clinical trials, Wegovy dosing follows a titration schedule: 0.25 mg weekly for 4 weeks, increasing to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg weekly. This gradual increase minimizes gastrointestinal side effects, which are the most common adverse reaction.

Research-grade semaglutide requires reconstitution with bacteriostatic water and refrigerated storage at 2-8°C. Researchers should note that compounded and research-grade semaglutide has not undergone the same quality controls as FDA-approved formulations.

For research reference only. Not medical advice. Not for human consumption.